Cabio Biotech, STAR Market-listed biotechnology company, industrializes arachidonic acid, DHA, beta-carotene and other products for nutrition and health food developers.
Algae DHA and DHA algal oil powder are plant-based omega-3s, free from mercury and perfect for vegans. They support brain, heart, and eye health, and are ideal for pregnant women, kids, and health-conscious adults. Versatile and eco-friendly.
Cabio, a leading algae DHA powder supplier and algal oil powder manufacturer, offers high-quality, plant-based nutrition. Specialising in algae oil powder, Cabio provides sustainable, eco-friendly ingredients for the health and wellness industries.
Cabio Biotech develops products for human and animal nutrition, personal care, and synthetic biology, leveraging nearly 20 years of biotechnology expertise.
2′-Fucosyllactose (2′-FL), a breast milk oligosaccharide, supports gut health, immunity, and brain development in infants while aiding digestion and allergy defense in adults.
Human Milk Oligosaccharides (HMOs) are prebiotics in breast milk that support infant development. Formula with HMO mimics breast milk’s composition, offering similar benefits.
Modern infant formulas increasingly include Human Milk Oligosaccharides (HMOs) to replicate breast milk’s nutritional profile, providing benefits for formula-fed infants.
The Industry Chain Technology Transfer Platform connects research and commercialization in biotechnology, advancing nutrient production and sustainability.
CABIO actively expands the international market, has many years of experience participating in Fi series exhibitions, and has reached stable cooperative relations with many well-known food and health enterprises worldwide.
In 2021, CABIO bucked the trend of the global pandemic with a consistently improving stable growth in income. CABIO targeted synthetic biology by investing more in R&D.
Cabio Biotech Wuhan Co experiences a 3.09% stock price increase during Tuesday’s trading session. The company’s performance reflects investor activity in the biotech sector. No specific catalysts for the rise are detailed in the report.
Cabio Biotech Co., Ltd. reports **CNY 90.17 million in sales** for the nine months ending September 30, 2026—a decline from **CNY 428.03 million** in the same period last year. The company also records a **net loss of CNY 238.96 million**, reversing a prior net income of **CNY 129.35 million** from 2025. Financial performance shows a sharp downturn in revenue and profitability.
CABIO unveils its life-stage nutrition ingredients portfolio at Fi Europe 2025 in Paris. The Chinese biotech company also opens its new Global Headquarters in Wuhan, expanding its focus on synthetic biology innovation.
CABIO showcases its **NeoHMOs®** biotech product at **Food Ingredients Europe** in Frankfurt, Germany. The company, listed on China’s Science and Technology Innovation Board (stock code: 688089), expands its international presence through participation in global trade events like **SupplySide West** in Las Vegas. Its **Human Nutrition Business Unit** targets long-term partnerships with international clients.
Nourish Ingredients partners with Cabio to enter the Chinese market and expand plant-based meat distribution. The collaboration marks the companies’ first cross-continental joint effort, aiming to broaden their global reach in the alternative protein sector.